| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 223.95 | 14.5% | 19.7% |
| Total Income | 228.26 | 13.8% | 19.0% |
| Expenditure | 164.41 | 3.3% | 14.2% |
| PBT | 63.85 | 81.9% | 33.5% |
| Net Profit | 48.70 | 73.6% | 125.8% |
| OPM | 33.53% | 7.10pp | 2.70pp |
| NPM | 21.34% | 7.35pp | 10.09pp |
| EPS | 2.99 | 64.3% | 28.3% |
Thyrocare FY26: Revenue Up 20%, PAT Surges 128%
07 May 2026 · 7 May, 6:41 pm
Summary
Thyrocare Technologies Limited announced robust financial results for Q4FY26 and the full fiscal year 2026. For Q4FY26, consolidated revenue grew 20% year-on-year to ₹223.95 crore, driven by strong performance in the Pathology segment. Profit After Tax (PAT) showed exceptional growth, surging 128% year-on-year to ₹48.70 crore, while EBITDA increased by 31% to ₹75.09 crore. For the entire fiscal year 2026, the company reported a consolidated revenue of ₹829.04 crore, up 21% YoY, with PAT rising 81% to ₹162.85 crore and EBITDA growing 38% to ₹262.04 crore. Management highlighted a strong focus on operational efficiency, network expansion, and the strategic strengthening of its specialty diagnostics portfolio, including entry into genomics, as key drivers for this performance.
Key Highlights
- 1
Thyrocare Technologies Limited reported consolidated revenue of ₹223.95 Cr for Q4FY26, registering a strong 20% year-on-year growth, primarily driven by a 21% increase in the Pathology segment.
- 2
For the fourth quarter of fiscal year 2026, consolidated EBITDA rose by 31% year-on-year to ₹75.09 crore, while Profit After Tax (PAT) surged by an impressive 128% year-on-year to ₹48.70 crore.
- 3
The company processed 59.0 million tests in Q4FY26, marking a significant 29% year-on-year growth and reinforcing its volume leadership in the diagnostics industry.
- 4
For the full fiscal year 2026, consolidated revenue grew by 21% year-on-year to ₹829.04 crore, with pathology franchise revenue up 18% YoY and partnership revenue up 32% YoY.
- 5
Full-year FY26 consolidated EBITDA increased by 38% year-on-year to ₹262.04 crore, and Profit After Tax grew by 81% year-on-year to ₹162.85 crore.
- 6
Thyrocare strengthened its specialty portfolio by expanding advanced allergy testing and foraying into genomics with the launch of Non-invasive Pre-Natal Testing (NIPT).
- 7
The company achieved Six Sigma quality standards by reducing complaints per million tests to 3.1, a 34% year-on-year reduction, with an Average Turnaround Time (ATAT) of 3.43 hours.
Management Comments
Rahul Guha
Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.
Informational and educational content only. Not investment advice.